Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of “Hold” from Analysts

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has been given a consensus rating of “Hold” by the ten analysts that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $11.33.

A number of equities research analysts have recently weighed in on ZNTL shares. UBS Group downgraded Zentalis Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the stock from $28.00 to $5.00 in a research note on Thursday, June 20th. Oppenheimer lowered their price objective on Zentalis Pharmaceuticals from $50.00 to $25.00 and set an “outperform” rating on the stock in a report on Tuesday, June 18th. Wells Fargo & Company lowered Zentalis Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $29.00 to $9.00 in a report on Tuesday, June 18th. Stifel Nicolaus lowered their target price on Zentalis Pharmaceuticals from $32.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, June 18th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $8.00 target price (down previously from $38.00) on shares of Zentalis Pharmaceuticals in a report on Tuesday, June 18th.

Zentalis Pharmaceuticals Trading Up 2.4 %

Shares of Zentalis Pharmaceuticals stock opened at $4.19 on Tuesday. The stock has a 50-day moving average price of $9.95 and a 200 day moving average price of $12.54. The company has a market cap of $297.62 million, a P/E ratio of -1.26 and a beta of 1.71. Zentalis Pharmaceuticals has a 1 year low of $3.93 and a 1 year high of $29.04.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings results on Tuesday, May 7th. The company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.91. The firm had revenue of $40.56 million for the quarter, compared to analysts’ expectations of $35.00 million. During the same period last year, the business earned ($1.07) earnings per share. On average, equities analysts forecast that Zentalis Pharmaceuticals will post -2.72 earnings per share for the current fiscal year.

Insider Transactions at Zentalis Pharmaceuticals

In related news, insider Diana Hausman sold 3,356 shares of the firm’s stock in a transaction that occurred on Thursday, May 9th. The stock was sold at an average price of $12.62, for a total transaction of $42,352.72. Following the completion of the transaction, the insider now owns 373,876 shares in the company, valued at approximately $4,718,315.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, insider Diana Hausman sold 3,356 shares of the firm’s stock in a transaction that occurred on Thursday, May 9th. The stock was sold at an average price of $12.62, for a total transaction of $42,352.72. Following the completion of the transaction, the insider now owns 373,876 shares in the company, valued at approximately $4,718,315.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Cam Gallagher sold 9,597 shares of the firm’s stock in a transaction that occurred on Friday, May 31st. The stock was sold at an average price of $11.98, for a total value of $114,972.06. Following the transaction, the chief financial officer now owns 633,680 shares of the company’s stock, valued at approximately $7,591,486.40. The disclosure for this sale can be found here. 6.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Several institutional investors have recently bought and sold shares of the business. ProShare Advisors LLC raised its position in Zentalis Pharmaceuticals by 9.0% in the 1st quarter. ProShare Advisors LLC now owns 15,436 shares of the company’s stock valued at $243,000 after purchasing an additional 1,274 shares during the last quarter. Exchange Traded Concepts LLC raised its position in Zentalis Pharmaceuticals by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 5,989 shares of the company’s stock valued at $91,000 after purchasing an additional 1,519 shares during the last quarter. Quest Partners LLC bought a new position in Zentalis Pharmaceuticals in the 4th quarter valued at $38,000. Tower Research Capital LLC TRC raised its position in Zentalis Pharmaceuticals by 252.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,615 shares of the company’s stock valued at $55,000 after purchasing an additional 2,589 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Zentalis Pharmaceuticals by 0.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 445,823 shares of the company’s stock worth $6,754,000 after acquiring an additional 3,759 shares during the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.